88 results about "Abnormal cells" patented technology

The embodiment of the application discloses an abnormality detection method and device for cell entering a shell, electronic equipment and a storage medium. The method comprises the following steps: acquiring detection data in the process that a cell entering shell machine drives the cell to enter a battery shell; generating one or more to-be-detected curves according to the detection data; detecting the one or more to-be-detected curves respectively according to historical detection data to obtain a detection result corresponding to each to-be-detected curve; and determining an abnormality result of the cell entering the shell according to the detection result corresponding to each to-be-detected curve. The embodiment of the application can improve the accuracy of the abnormal cell judgment. The above judgment process does not need manual inspection, improves the intelligent degree of the cell detection process, can effectively determine the main abnormal problems in the production process, and can be solved in a targeted manner, thereby improving the accuracy and efficiency of the abnormal detection of the lithium cell entering the shell process.

The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

A polymeric nanoparticle is disclosed which comprises:(i) at least one disease-associated antigen which is capable of producing a T-cell response, wherein the disease-associated antigen is encapsulated in the nanoparticle;(ii) at least one adjuvant; and(iii) a dendritic cell targeting moiety which is attached to the outer surface of the nanoparticle.Use of the nanoparticle for treating diseases associated with abnormal cell growth or an infection is also disclosed.

The invention discloses a direct counting method and device for detecting the number of fluorescence-labeled rare abnormal cells in a blood sample. Aiming at the problem that direct counting of low-abundance cells is difficult to realize in a conventional blood container by a traditional detection means, the method realizes rapid and direct counting of rare abnormal cells by performing narrow-band filtering, efficient collection and high signal-to-noise ratio detection on a fluorescence signal emitted by a static blood sample. The device comprises a lighting source module, an exciting light and emitted light narrow-band filtering module, a light beam collimation and beam expansion module, a sample bearing module, an emitted light collection and detection module and a data processing and counting module. Accurate counting of the extremely-low-abundance fluorescence labeling abnormal cells can be completed in a conventional transparent container without flow sorting or complex treatment of a blood sample, and the method has the advantages of being easy and convenient to operate, high in detection speed, suitable for clinical screening and the like.

The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

The present disclosure relates to novel compounds that act as modulators of cereblon (CRBN). The compounds promote CRBN-mediated ubiquitination and proteasomal degradation of oncogenic proteins such as GSPT1 and MYC, thereby suppressing abnormal cell growth. Pharmaceutical compositions containing the compounds and methods of using the compositions for the treatment of cancers, particularly solid tumors, are also provided.

The present disclosure relates to compounds of Formula (I′):and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

The invention provides a genetic engineering strain and a construction method thereof, the strain is a target gene deleted strain obtained by knocking out a target gene in a rod-shaped bacterial strain, and the target gene is one of minC and minD genes or a gene combination thereof. According to the present invention, the minC and / or minD gene deletion strain is obtained by knocking out the minC and / or minD gene in the rod-shaped bacterial strain, such that cell division abnormality can be caused, chromosome-free small cells are generated, and the small cells have characteristics of biological activity, no chromosome DNA, and no growth or division propagation. The small cells can generate smaller body immune response, and meanwhile, the LPS modified by the small cells can generate smaller cytotoxic reaction, so that side effects can be greatly reduced when the small cells are applied to human or animal bodies.

Disclosed herein is a method for training a network to detect and classify abnormal pathologies in images if cells. Specifically, the network uses a deep framework optimally trained to detect and classify abnormal cervical cells in pap smear images.

The invention discloses a method and a device for judging network access perception degradation, electronic equipment and a storage medium. The method comprises the steps that a first object of a target line is determined, the target line comprises a plurality of first cells, and the first cells are the network coverage range of a communication base station of each high-speed rail station on the target line; determining a third index based on the association degree of the first index and the second index; the first index is a key quality index of each first cell network, and the second index is an index of a network operation state and network technical performance of each first cell; the third index is a first index strongly related to the internet surfing perception of the first object; determining a first index threshold value of the third index, and determining a second object based on the third index and the first index threshold value; the second object is an object with degraded internet access perception in the first object; and determining the distribution condition of the second object in each first cell, and determining an abnormal cell according to the distribution condition. According to the method, the wireless network sensing condition of the high-speed rail line can be accurately judged.

A pyrrolopyrimidine or pyrrolopyridine derivative and its medical use. Specifically, the compound has the structure shown in formula I, has good inhibitory effect on focal adhesion kinase (FAK), and can inhibit its related signal pathways, and can be prepared for treating or preventing diseases related to cancer, pulmonary arterial hypertension, pathological angiogenesis, etc., and can be particularly used for treating diseases caused by excessive or abnormal cell proliferation, such as tumors or cancers.

The present disclosure relates to a Camptothecin compound having anti-tumor activity, a preparation method therefor, and an application thereof. Specifically, the present disclosure relates to a compound as shown below or a pharmaceutically acceptable form thereof, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof. The compound can be used as a drug for treating diseases in abnormal cell proliferation,

This invention relates to the crystalline form (form 7) of the free base of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H-8,4-(methiminated bridged)pyrazolo[4,3-h][2,5,11]benzoxazadiazetatetracycline-3-carboxynitrile (lorlatinib). The invention also relates to pharmaceutical compositions comprising form 7 and to methods of treating abnormal cell growth in mammals, such as cancer, using form 7 and such compositions.

The application relates to the technical field of image processing, in particular to an abnormal cell screening method and system based on image analysis, which comprises the following steps: acquiring continuous image frames of a staining process, extracting average optical density, integral optical density and chromatin gray standard deviation of sample cells as staining parameters, and acquiring chromatin texture; forming a staining parameter space curve with the change of the staining parameters over time, fitting to obtain a continuous staining curve; aligning and fitting the continuous staining curve with a standard parameter curve calibrated in advance to obtain a coordinate transformation vector; acquiring an image frame after the completion of the staining, performing standardization correction on the staining parameters of the to-be-tested cells by using the coordinate transformation vector to obtain chromatin texture features, and then performing feature comparison and identification on abnormal cells. The application reduces the staining sensitivity difference caused by biological factors such as individual gene expression difference, different cell membrane protein compositions and pH value changes, and eliminates the influence of staining condition difference and equipment difference among different laboratories on the screening result.

The application relates to an abnormal cell identification method, device, equipment, storage medium and program product. The method comprises the following steps: collecting parameters of multiple dimensions of a battery cluster in a same string loop at each moment during a charging process; the multiple dimensions at least include voltage, internal resistance and temperature; mapping the parameters of the multiple dimensions at each moment to a three-dimensional feature space constructed according to the voltage, the internal resistance and the temperature; determining discrete data points according to density information of each data point in the three-dimensional feature space; and determining a defective cell according to the discrete data points. The method can more comprehensively capture abnormal features of the cell, thereby improving the accuracy of defective cell identification.

This invention discloses a novel application of the RNA-binding protein HNRNPA1 in regulating copper death in synovial fibroblasts of rheumatoid arthritis (RA-FLS). Overexpression of HNRNPA1 recognizes and binds to the m6A modification site of SLC3A2 mRNA, enhancing its transcript stability, restoring the expression of SLC3A2 and copper death-related proteins, reducing MDA levels, increasing copper ion concentration and the activity of antioxidant enzymes SOD and POD, thereby repairing mitochondrial ultrastructural damage, inhibiting abnormal cell proliferation, and inducing apoptosis. Reversal experiments confirmed that knocking down SLC3A2 reverses the above effects, indicating that SLC3A2 is a core downstream target of HNRNPA1-mediated copper death. This invention reveals for the first time the decisive role of the HNRNPA1-SLC3A2-copper death axis in the pathological phenotype of RA-FLS, providing a new target for molecular intervention in rheumatoid arthritis.

The present application relates to the use of antibody-drug conjugates, wherein the antibody is a bispecific antibody or an antigen-binding fragment thereof comprising a first antigen-binding domain that specifically binds to c-MET and a second antigen-binding domain that specifically binds to EGFR, in treating diseases associated with abnormal cell activity in subjects, such as tumor diseases, wherein the relevant genes of the subjects suffering from the tumor diseases are mutant or wild-type, and they have undergone or have not undergone first-line or second-line treatment.

The invention discloses skin mucosa maintenance liquid capable of killing fungi and HPV (human papillomavirus) as well as a preparation method and application of the skin mucosa maintenance liquid, and belongs to the technical field of sterilization and virus removal. The skin mucosa maintenance liquid is prepared from octanol ether, benzalkonium bromide, phenoxyethanol, yermate, parachlorometaxylenol, taetinic acid, chitosan, keratinase, fluconazole, glycerol, borneol, menthol, absolute ethyl alcohol and tween-40. Wherein the skin mucosa maintenance liquid has an effect of regulating apoptosis induction on abnormal cells and an effect on vaginal flora, and has an obvious inhibition effect on cervicitis and colpitis mycotica, namely an anti-inflammatory effect; meanwhile, apoptosis of cells containing HPV16 and HPV18 genes can be induced, shedding of abnormal cells is promoted, diseased cells are killed, and vaginal tissues with pathological changes are removed.

The present invention relates to compounds of formula (I)or pharmaceutically acceptable salts thereof, wherein Ring A, R1-R8, and n are defined herein. The novel benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in patients.

This invention relates to the field of immunoassay technology, specifically to a multicolor fluorescent diagnostic reagent for detecting PAP. The multicolor fluorescent diagnostic reagent includes Hurst dye, wheat germ lectin, fluorescein isothiocyanate, a counterstaining agent, an organic solubilizer, and a humectant. This invention incorporates multiple fluorescent dyes, enabling rapid and effective detection of glycoprotein signals in PAP patient specimens. Simultaneously, it clearly displays cell morphology in the specimens, allowing for timely exclusion of bacteria, fungi, and abnormal cells, thus helping doctors quickly and accurately determine the type of PAP in patients. Compared to the traditional PAS staining method, the multicolor fluorescent diagnostic reagent provided by this invention uses a one-step staining method, which is simple to operate, has a short detection time, and allows for rapid observation of test results, facilitating timely diagnosis and treatment for patients.

The application discloses a trispecific antibody combining CD3, CD19 and BCMA and application thereof. The trispecific antibody comprises a first antigen binding domain combining CD3, a second antigen binding domain combining CD19, a third antigen binding domain combining BCMA and a heterodimeric Fc region. The application recruits and activates T cells through the CD3 binding domain, and realizes broad-spectrum recognition and combination of the whole abnormal B cell lineage from early B cells to terminally differentiated plasma cells through the CD19 and BCMA double binding domains, can more thoroughly eliminate pathological B cells, overcomes the antigen escape or drug resistance problems possibly existing in single target treatment by using multiple synergies, and provides a novel antibody drug for diseases such as multiple myeloma, B cell lymphoma and B cell related autoimmune diseases.

The present invention relates, in part, to methods, compounds, and compositions of a DDR pathway inhibitor in combination with a dual RAF / MEK inhibitor, for treating abnormal cell growth (e.g., cancer).

The invention relates to a camptothecin compound and a conjugate thereof, or a tautomer, an enantiomer and a diastereoisomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition, a preparation method and an application thereof. The compounds and conjugates can be used for treating proliferative diseases associated with abnormal cell activity.

The application discloses a blood smear white blood cell classification counting method and system based on image analysis, and belongs to the technical field of medical image processing. The method comprises the following steps: after collecting a peripheral blood smear image, performing adaptive background correction and color standardization pretreatment; detecting and segmenting each white blood cell through an instance segmentation network; extracting three-dimensional features of nuclear morphology, cytoplasmic staining and nuclear-cytoplasmic ratio and adaptively fusing; adopting a cascade classifier to perform five-class white blood cell classification and abnormal morphology identification; and counting and labeling suspected abnormal cells for review. The classification coincidence rate of the application reaches more than 95%, can effectively identify abnormal morphologies such as atypical lymphocytes, immature cells and toxic granules, and provides technical support for blood tests at the grassroots level.

The invention relates to the technical field of image processing, in particular to an abnormal cell screening method and system based on image analysis, and the method comprises the steps: obtaining continuous image frames of a dyeing process, extracting the average optical density, integral optical density and chromatin gray standard deviation of sample cells as dyeing parameters, and obtaining chromatin textures; the dyeing parameters are changed along with time to form a dyeing parameter space curve, and a continuous dyeing curve is obtained through fitting; aligning and fitting the continuous dyeing curve and a pre-calibrated standard parameter curve to obtain a coordinate transformation vector; and obtaining a dyed image frame, carrying out standardized correction on a to-be-detected cell dyeing parameter by using the coordinate transformation vector to obtain a chromatin texture feature, and carrying out feature comparison to identify an abnormal cell. According to the method, the dyeing sensitivity difference caused by biological factors such as individual gene expression difference, cell membrane protein composition difference and pH value change is reduced, and the influence of dyeing condition difference and equipment difference among different laboratories on screening results is eliminated.

The embodiment of the invention relates to a battery cell inconsistency detection method and system based on multi-mode time sequence analysis, and the method comprises the steps: obtaining time sequence data streams of a plurality of battery cells, and constructing a multi-dimensional feature matrix; segmenting the time sequence data stream by adopting a plurality of N-point sliding windows, and carrying out normalization processing on the feature matrix; an LSTM self-encoder framework is constructed; carrying out multi-dimensional inconsistency analysis on the battery cell; according to the invention, the multi-modal time sequence analysis and the depth self-encoder LSTM are combined and applied to the cell inconsistency detection, and the accurate positioning of the abnormal cell is realized through the multi-modal time sequence analysis of the key parameters of the cell, the calculation of the weighted comprehensive score and the analysis of the comprehensive inconsistency of the cell. Therefore, the problem of cell inconsistency can be found early and the maintenance decision can be guided.

The present disclosure relates to compounds of Formula (I') and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of making these compounds, compositions comprising these compounds, and methods of using the same to prevent or treat abnormal cell growth in mammals, particularly humans.

The application provides an inflammation hot spot area identification method and device, equipment and storage medium, relating to the technical field of spatial transcriptomics. The inflammation hot spot area identification method comprises: obtaining spatial transcriptome data; calculating the spatial inflammation score coefficient of each cell to be tested; screening out abnormal cells; performing clustering processing to obtain cell clusters; and determining the inflammation hot spot area in the tissue to be tested according to the spatial enrichment characteristics. The inflammation score coefficient is calculated by deeply coupling the spatial coordinates and the gene expression amount, and the real inflammation microenvironment of the cell is accurately restored. An abnormal baseline model is constructed in combination with the healthy control group data, an objective screening standard is established, background noise is effectively eliminated, and high-precision extraction of abnormal cells is realized. Further, through clustering and spatial enrichment characteristic analysis, the spatial boundary of the inflammation hot spot area is accurately determined, the defects of inaccurate evaluation and fuzzy boundary of the traditional technology are effectively overcome, and the identification accuracy is greatly improved.

The present invention relates to a pyrrolopyrimidinone derivative or pharmaceutically acceptable salt thereof, a composition for preventing or treating cancer comprising the derivative as an active ingredient, and the like, the pyrrolopyrimidinone derivative of the present invention being highly effective in inhibiting ENPP1 activity. Therefore, the present invention can be used for the purpose of treating, preventing, and alleviating cancerous diseases caused by abnormal cell growth. In addition, the pyrrolopyrimidinone derivative and pharmaceutically acceptable salt thereof of the present invention effectively inhibit ENPP1 to activate the STING pathway, and thus can be effectively used in preventing or treating cancer.

The application discloses a method for simultaneously identifying cell subgroups and related factor phosphorylation levels. The method simplifies the protein phosphorylation flow cytometry staining step without affecting the staining effect, can simultaneously detect 17 stained cells, and simultaneously saves cost and is more efficient. The method provided by the application can provide more accurate distinguishing ability, can obtain more information from a small cell sample, can detect abnormal cells at a low level, increases laboratory efficiency, is especially suitable for the research of the immune system, and has a wide prospect.